Andrew Drechsler

Andrew Drechsler has served as a director since August 2020. Mr. Drechsler has served as Chief Financial Officer of Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, since September 2017. From 2012 to April 2017, Mr. Drechsler was the Chief Financial Officer at Insmed Incorporated, a publicly traded biopharmaceutical company dedicated to improving the lives of patients with orphan pulmonary disease. Prior to that, Mr. Drechsler was Chief Financial Officer at VaxInnate, a privately held biotechnology company in Cranbury, NJ that is pioneering a breakthrough technology platform for use in developing novel and proprietary vaccines, where he played a critical role in securing approximately $200 million in U.S. government funding for the company’s vaccine programs. From 2005 to April 2007, Mr. Drechsler served as Chief Financial Officer for Valera Pharmaceuticals, Inc. where he helped Valera raise funding through an initial public offering.

Mr. Drechsler received a B.S. in Accountancy from Villanova University, graduating Magna Cum Laude. He obtained his Certified Public Accountant license in the State of New Jersey and actively raises funds for and awareness of juvenile diabetes via the Juvenile Diabetes Research Foundation.